METHOD OF PREDICTION RISK OF ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS FOR 6 YEARS AFTER SCHEDULED ENDOVASCULAR MYOCARDIUM REVASCULARIZATION Russian patent published in 2018 - IPC A61B5/00 A61B5/145 

FIELD: medicine.

SUBSTANCE: following clinical characteristics are determined for the patient: presence or absence of a hereditary predisposition to the development of cardiovascular diseases (x₁); percutaneous coronary interventions with statin intake or without it (x₂); initial level of postprandial glucose in blood in mmol/l (x₃); presence or absence of a high risk of contrast-induced nephropathy development (x₄). The probability of risk is calculated by the formula: P = e^F/(1+e^F). At that, P is the probability of adverse cardiovascular and cerebrovascular events development within 6 years after scheduled percutaneous coronary interventions; e is the base of the natural logarithm (e=2.7183); F is the calculated value of the function, equal to F(x)=b₀+b₁⋅x₁+b₂⋅x₂+b₃⋅x₃+b₄⋅x₄. If P is less than 0.56, a high risk of adverse cardiovascular and cerebrovascular events is predicted within 6 years after scheduled endovascular myocardium revascularization. If P≥0.56, the course of the disease after endovascular intervention on the coronary arteries is favourable.

EFFECT: method allows to predict the onset of adverse cardiovascular and cerebrovascular events within 6 years after scheduled endovascular myocardium revascularization, which ensures timely use of more active follow-up and treatment strategies.

2 tbl